Alexander Levitzki
Alexander Levitzki (born August 13, 1940 in Jerusalem ) is an Israeli biochemist, known for developing new cancer therapies.
Levitzki, son of mathematician Jacob Levitzki , studied biochemistry at the Hebrew University (master's degree in 1963), where he received his doctorate summa cum laude in 1968 (at the Hebrew University and at the Weizmann Institute). After that he was a postdoctoral fellow with Daniel E. Koshland at the University of California, Berkeley until 1971 . He became a senior scientist in 1970 and an associate professor at the Weizmann Institute of Science in 1974 . In 1974 he became associate professor and in 1976 professor at the Hebrew University in Jerusalem . He was visiting professor at various California universities (Berkeley, Stanford, San Francisco) and visiting scholar at the NIH in Bethesda .
Levitzki is known for developing inhibitors of various protein kinases that are produced in certain cancers. This resulted in the drug Gleevec from Novartis (1996) against the leukemia variant CML .
Since 1982 he has been an elected member of the European Molecular Biology Organization . In 2005 he received the Wolf Prize in Medicine. In 1990 he received the Israel Prize and the Rothschild Prize . He is a member of the Israel Academy of Sciences , a full member of the Academia Europaea since 2010 and a Foreign Associate of the National Academy of Sciences since 2017 .
Web links
Individual evidence
- ^ Directory of members: Alexander Levitzki. Academia Europaea, accessed October 1, 2017 .
| personal data | |
|---|---|
| SURNAME | Levitzki, Alexander |
| BRIEF DESCRIPTION | Israeli biochemist |
| DATE OF BIRTH | August 13, 1940 |
| PLACE OF BIRTH | Jerusalem |